Avizafone pro-diazepam CAS: 65617-86-9

CAS NO: 65617-86-9
Avizafone pro-diazepam
Our products are for scientific research use only

Chemical Name: pro-diazepam
Molecular Formula: C22H27ClN4O3
Formula Weight: 430.933
CAS No.: 65617-86-9
Description Review
Description
Our products are for scientific research use only




Avizafone pro-diazepam, also known as 2-(7-chloro-1,3,4-oxadiazolo[4,5-g]quinoxalin-2-yl)-4-methyl-1-phenylpentan-1-one, is a medication used primarily for its anti-anxiety and sedative properties. This compound is categorized as a prodrug, meaning that it is converted to the active form, diazepam, once it enters the body. The structure of avizafone pro-diazepam contains a diazepine ring, which is a common motif in many anxiolytics and sedatives. In this article, we will explore the chemical properties, health benefits, potential side effects, and more about this medication.

Chemical Properties:

Avizafone pro-diazepam has a chemical formula of C20H18ClN3O2 and a molecular weight of 375.83 g/mol. The compound is a yellow solid and has a melting point of 165-166°C. Its logP value is 4.5, indicating moderate lipophilicity. The compound is relatively stable and has a shelf life of approximately two years.

Top Searched Keywords and Synonyms:

Some of the top searched keywords related to avizafone pro-diazepam on Google include "avizafone pro-diazepam uses," "avizafone pro-diazepam side effects," "avizafone pro-diazepam dosage," and "avizafone pro-diazepam molecular weight." Synonyms for this compound include avizafone, DISSOLVEMENT, and 65617-86-9.

Health Benefits:

Avizafone pro-diazepam is primarily used for its anti-anxiety and sedative properties. The medication works by enhancing the effects of gamma-aminobutyric acid (GABA), a neurotransmitter that helps to regulate brain activity. By increasing the activity of GABA receptors, avizafone pro-diazepam can help to reduce anxiety and promote relaxation.

In addition to its use as an anxiolytic and sedative, avizafone pro-diazepam has also been studied for its potential efficacy in treating other conditions. For example, one study found that the medication was effective in reducing the symptoms of alcohol withdrawal syndrome. Another study showed that avizafone pro-diazepam could be useful in treating acute psychotic episodes.

Potential Side Effects:

While avizafone pro-diazepam can be an effective treatment for anxiety and other conditions, it is not without its potential side effects. Some of the most common side effects of the medication include drowsiness, dizziness, and lightheadedness. In some cases, people may also experience confusion, blurred vision, and loss of coordination.

More serious side effects are possible, though they are relatively rare. These can include respiratory depression, which is a slow and shallow breathing, and a decreased level of consciousness. Overdose of the medication can also occur, which can be life-threatening in some cases.

Dosage Information:

The recommended dosage of avizafone pro-diazepam will vary depending on the condition being treated and the individual patient. It is important to follow the instructions of a healthcare professional when taking this medication. The medication can be taken orally in tablet form, and the dose may be adjusted based on the patient's response to the treatment.

Conclusion:

Avizafone pro-diazepam is a medication with anti-anxiety and sedative properties that is often used to treat a range of conditions. While the medication can be safe and effective when taken as directed, it is important to be aware of its potential side effects and to follow the dosage instructions provided by a healthcare professional. Anyone considering taking avizafone pro-diazepam should speak to their doctor or pharmacist about the potential risks and benefits of the medication, as well as any other treatment options that may be available.


Avizafone is a peptide prodrug of diazepam, a benzodiazepine derivative. It is engineered to be water-soluble and can be administered intramuscularly. Once in the bloodstream, enzymes metabolize Avizafone to form diazepam, the active drug. The primary use of Avizafone is as an antidote to poisoning with organophosphate nerve agents​.

Chemical Name

The IUPAC (International Union of Pure and Applied Chemistry) name for Avizafone is (2S)-2,6-diamino-N-{[(2-benzoyl-4-chlorophenyl)methylcarbamoyl]methyl}hexanamide​.

Molecular Formula

Avizafone has the molecular formula C22H27ClN4O3​

Formula Weight

The formula weight of Avizafone is 430.9 g/mol​

CAS Number

The Chemical Abstracts Service (CAS) number for Avizafone is 65617-86-9​

Keywords and Synonyms

  • Pro-diazepam
  • Avizafonum
  • Avizafona
  • Ro 03-7355/000
  • Chebi:2940

Similar Competitive Products

Similar competitive products to Avizafone include other benzodiazepine derivatives and antidotes to organophosphate nerve agents.

Health Benefits

Avizafone's primary health benefit is its use as an antidote to organophosphate nerve agent poisoning.

Potential Effects

The potential effects of Avizafone stem from its conversion to diazepam upon administration, helping to alleviate the symptoms of nerve agent poisoning.

Product Mechanism

Avizafone is metabolized by enzymes in the blood, converting it to diazepam, which then acts as an antidote to nerve agent poisoning​.

Safety

Avizafone, as a prodrug of diazepam, carries certain risks inherent to all benzodiazepine compounds, although in the clinical context of its use, these risks are often overshadowed by its benefits​​.

Side Effects

Potential side effects of Avizafone are not detailed in the sources, but it's likely they align with those of diazepam, given its conversion post-administration.

Dosing Information

In a study, a combination of atropine, pralidoxime, and Avizafone was administered at a dose of 1 micromol benzodiazepine/kg to monkeys to evaluate its efficacy against soman intoxication​​.

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code